Navigation Links
Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
Date:1/5/2009

cutive weeks of a four week cycle, over a range of doses. The primary objectives of the study will be to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of CX-4945, and to define the phase II dose. The secondary objectives are to characterize the pharmacokinetics, as well as observe for signs of anti-tumor activity via pharmacodynamic as well as radiographic assessments.

"CK2 is of central importance in driving cancer cell proliferation as well as in angiogenesis. As such, CX-4945 is a truly novel therapeutic, particularly against cancers and in other indications mediated by IL-6 and IL-8," added Dr. Daniel Von Hoff, Cylene's Co-Founder and Vice President, Medical Affairs.

About CX-4945, an oral CK2 protein kinase inhibitor

CX-4945 is a first-in-class small molecule that has been optimized to selectively inhibit CK2 activity. The CK2 protein kinase plays a multifunctional role in cell cycle regulation, signal transduction, transcriptional control, angiogenesis, apoptosis and inflammation. Because CK2 contributes to the cancer phenotype via multiple cellular events, CX-4945 has been designed with the objective of creating a multifunctional inhibitor by targeting a single protein and affecting potentially many cancers. CX-4945 demonstrates broad spectrum anti-proliferative activity against diverse cancer cell lines, and the data attribute the anti-tumor activity of CX-4945 to intracellular inhibition of the CK2 enzyme.

About Cylene Pharmaceuticals, Inc.

Cylene Pharmaceuticals is a biotech pharmaceutical company dedicated to the discovery, development and commercialization of targeted small-molecule drugs to treat life-threatening cancers. Cylene has created a diverse portfolio of product candidates, including novel inhibitors of cancer-linked serine/threonine protein kinases, as well as innovative nucleolus targeting agents (NTAs) that target the ab
'/>"/>

SOURCE Cylene Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
2. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
3. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
4. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
5. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
6. Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
7. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
8. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
9. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
10. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
11. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013  Avanir Pharmaceuticals, Inc. (NASDAQ: ... overview of the company at the following conferences. ... Presentation date: Wednesday May 29, 2013 , Presentation time: ... Healthcare Conference , Presentation date: Wednesday June 5, 2013 ... A live webcast and 30-day archive of ...
(Date:5/22/2013)... PHILADELPHIA , 22. Mai 2013 /PRNewswire/ ... Sitz in Barcelona , ... aufzeigt, dass eine höhere Dosis von PROLASTIN©-C ... Patienten mit Alpha1-Antitrypsinmangel (AAT) auf ein Niveau ... normal bezeichneten Bereichs liegt. ATT-Mangel ist eine ...
(Date:5/22/2013)...  Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company ... medical needs, today announced the appointment of ... Board of Directors. Dr. Almenoff has extensive experience in ... drug development. "We are delighted to ... Taraporewala, CEO of Ohr Pharmaceutical. "She offers tremendous expertise ...
Breaking Medicine Technology:Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors 2Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors 3
... PXS) today announced significant results of pooled data from ... of Bronchitol (inhaled mannitol) in people with cystic fibrosis. ... the first time at the North American Cystic Fibrosis ... results from the second trial (CF302) have been released ...
... Oct. 22 INVO Bioscience, Inc. (OTC Bulltin Board: ... for patients diagnosed with infertility, today announced that Dr. ... (CECOFLES LTDA) will present the results of the first ... INVO Bioscience,s INVOcell technology at the 66th Annual Meeting ...
Cached Medicine Technology:Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 2Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 3Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 4Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 5INVOcell Study Results to be Reported at the Annual Meeting of The American Society of Reproductive Medicine 2INVOcell Study Results to be Reported at the Annual Meeting of The American Society of Reproductive Medicine 3
(Date:5/22/2013)... anti-cancer drugs to the "power plants" that make energy ... approach to preventing emergence of the drug-resistant forms of ... are reporting. That,s the conclusion of a new study ... , Shana Kelley and colleagues explain that doxorubicin ... the genes inside the nucleus of cancer cells. Cancer ...
(Date:5/22/2013)... 22, 2013 Digital Advertising Agency, ... of its social media management client, Primal Pit ... supply of the all-natural organic deodorant. The contest is ... the rapidly-growing start-up deodorant company based in Tampa, Florida. ... or sweepstakes on a Facebook page is a great ...
(Date:5/22/2013)... With the health of a growing fetus largely dependent on ... many women become hyperaware of everything that goes into their ... a pregnancy test. At no other time in life is ... caffeine, alcohol, and nicotine) stronger than during pregnancy. But how ... this increased awareness during pregnancy extend to the lotions, potions, ...
(Date:5/22/2013)... Garcinia cambogia select is a dual action ... the extra fat being stored in the body. For a ... This fat burner helps people in this regard by making ... Basically it does this by secreting a hormone serotonin which ... away from emotional overeating. In this way, it keeps a ...
(Date:5/22/2013)... NJ and Los Angeles, CA (PRWEB) May 22, 2013 ... of the board, The J. M. Smucker Company, and ... Lifetime Achievement Awards yesterday at the GS1 General Assembly ... Angeles, California. Mr. Smucker and Mr. Wegman were recognized ... of GS1 Standards - the most broadly used supply ...
Breaking Medicine News(10 mins):Health News:Social Media Management Firm, 21Digital, Launches National Facebook Sweepstakes for Client, Primal Pit Paste 2Health News:Fairhaven Health Launches New PregnancyPlus Natural Deodorant Designed Specifically for Pregnant Women 2Health News:Garcinia Cambogia Reviews Released Online for Fast Weight Loss Solution with Offer of Extra 3 Month Supply 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 3
... STOCKHOLM, March 25 Dr. Bindeshwar Pathak, founder of,Sulabh ... Stockholm Water,Prize Laureate. , To ... , As the Founder of ... around the world for his wide ranging work in ...
... PARSIPPANY, N.J., March 25 It,s a different era ... of an ever-changing industry while battling an uncertain economy. ... the key to retaining market share and maintaining hard-earned ... tools of pharmaceutical competitive intelligence. , ...
... Bulls Legend BJ Armstrong Rallies Students to Get Fit By ... Grant CHICAGO, March 25 Chicago Bulls legend BJ ... fitness game as part of a new national campaign called ... of a new partnership between the "got milk?" Body By Milk(R) ...
... thickness, study finds , , WEDNESDAY, March 25 (HealthDay News) -- ... be associated with a higher risk for depression, U.S. researchers ... 54, including those who did and did not have a ... depression in their family history had a 28 percent thinning ...
... Solution Offers Proactive Monitoring of Critical Systems to ... Patient Care EnhancementNEW YORK, March 25 CareTech ... and services provider for hospitals and health systems, ... desk solution across all hospitals that together comprise ...
... --Company Now Has Until October 26, 2009 to Regain Compliance ... 25 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today ... provides Peregrine with an additional three months to ... now has until October 26, 2009 to regain compliance with ...
Cached Medicine News:Health News:Indian Sanitation Innovator and Social Reformer Awarded 2009 Stockholm Water Prize 2Health News:Support at Fever Pitch for Dynamic, Fresh Approach to Pharmaceutical Competitive Intelligence 2Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Cesar E. Chavez Multicultural Center 2Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Cesar E. Chavez Multicultural Center 3Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Cesar E. Chavez Multicultural Center 4Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Cesar E. Chavez Multicultural Center 5Health News:Brain 'Thinning' May Indicate Susceptibility to Depression 2Health News:CareTech Solutions Launches Robust Service Desk Solution to Support Clinical Applications and Technology within Continuum Health Partners Hospitals 2Health News:CareTech Solutions Launches Robust Service Desk Solution to Support Clinical Applications and Technology within Continuum Health Partners Hospitals 3Health News:Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQ's Minimum Bid Price Rule 2
... Pipetman Ultra is a fully adjustable, air-displacement ... It is the latest member of the ... characteristics: robustness, accuracy, and precision. We also ... feedback from our customers. Eight models cover ...
... The AlphaPette Pipettor is the #1 ... Offers accuracy, comfort, and reliability. Continuously ... volume readout sub-micrometer. Easy interchangeable ejector ... tiny hands. Adjustable rapid pipet tip ...
... Finnpipette Focus from Thermo Labsystems was designed ... Advanced features such as the new ... adjustment on microvolumes help to define this ... pipettes. The new interchangeable handle plate offers ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,408-9) or contact custom...
Medicine Products: